Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOSAGE: Reduced vs Standard Dose Chemotherapy in Older Metastatic Colorectal Cancer
NCT06275958Phase 3Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jul 2024
- Primary completion
- Jun 2028
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine, oxaliplatin, fluorouracil in colorectal cancer (metastatic) (mCRC), sponsored by Leiden University Medical Center. Started Jul 2024; status: recruiting.
02
Drugs
capecitabineoxaliplatinfluorouracil
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT06275958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06275958.